Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9181228 | 0.88 | TAS1R3 (0.58) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL1101431 | 0.83 | MAPT (0.54) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL2361382 | 0.83 | MAPT (0.54) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL28562583 | 0.83 | MAPT (0.54) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL31430581 | 0.83 | MAPT (0.54) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL31314521 | 0.82 | TAS1R3 (0.52) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL10114288 | 0.82 | POLB (0.57) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL29784106 | 0.82 | TAS1R3 (0.57) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL703616 | 0.82 | TAS1R3 (0.57) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL15174576 | 0.81 | TAS1R3 (0.61) | ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| EP-3623371-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (CH) | 2020-03-18 | — | — | EP | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1718642-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005082901-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-0816348-B1 | Heterocyclic n-acetonylbenzamides and their use as fungicides | DOW AGROSCIENCES LLC (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1229028-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1229027-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1229037-A1 | Heterocyclic N-acetonylbenzamides and their use as fungicides | Dow AgroSciences LLC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-5811427-A | FUNGICIDES; CONTROLLING PHYTOPATHOGENIC FUNGI PARTICULARLY OF THE CLASS OOMYCETES | ROHM AND HAAS COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0816348-A1 | Heterocyclic n-acetonylbenzamides and their use as fungicides | ROHM AND HAAS COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, METTL16, TPMT | ALDH1A1 1686/4885SMN1; SMN2 720/4885RAB9A 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.